CanDapi Ltd. Develops the world’s most accurate dry powder inhaler, customized for your generic or novel inhaled medication. The inhaler is simple to use, suits every patient – from babies, through lung disease patients to the elderly – without the need of complicated user instructions. Furthermore, the product’s price is very affordable. CanDapi’s drug delivery method is based on an innovative technology which is different and therefore more efficient than other products in the market. The product’s efficiency is remarkably high and exceeds 80% for a variety of drug powders. The company is ISO 13485 certified. In addition, the product is patented and further regulatory steps are being taken nowadays: FDA, CE, Israeli Ministry of Health registration. In addition, Pre-Clinical and Clinical tests will begin in the near future. CanDapi Ltd. is based in Yeruham, in the south of Israel and is a part of the CanNegev startup incubator and of the Israeli Innovation Authority’s startup program.
